Xu Da-Ming, Chen Ling-Xiao, Zhuang Xiao-Yu, Han Hui, Mo Miao
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Front Oncol. 2024 Jul 17;14:1394260. doi: 10.3389/fonc.2024.1394260. eCollection 2024.
Penile cancer is a rare malignant tumor of the male urinary system. The treatment benefit of standard first-line chemotherapy is not ideal for patients with locally advanced or metastatic lymph nodes. Immunotherapy has brought new treatment strategies and opportunities for patients with penile cancer. At present, clinical studies on immunotherapy for penile cancer have been reported, and the results show that it is effective but not conclusive. With the development of immunotherapy and the progress of molecular research technology, we can better screen the immunotherapy response population and explore new combination treatment regimens to evaluate the best combination regimen and obtain the optimal treatment options, which is also an important research direction for the immunotherapy of penile cancer in the future.
阴茎癌是男性泌尿系统的一种罕见恶性肿瘤。对于局部晚期或有转移性淋巴结的患者，标准一线化疗的治疗效果并不理想。免疫疗法为阴茎癌患者带来了新的治疗策略和机遇。目前，已有关于阴茎癌免疫疗法的临床研究报道，结果显示其有效但尚无定论。随着免疫疗法的发展和分子研究技术的进步，我们能够更好地筛选免疫疗法反应人群，并探索新的联合治疗方案，以评估最佳联合方案并获得最优治疗选择，这也是未来阴茎癌免疫疗法的一个重要研究方向。
